Clinical trials: HIV Seronegative
HIV Prevention
Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)
This is the first-in-human clinical study to see if a single dose of an investigational enema made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable for use by healthy adults 18-45 years of age…
- Trial name
- PREVENT (NCT04032717)
- Testing
- Q-Griffithsin (Q-GRFT) enema
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Rhonda Brand
HIV, Mental Health
Engaging Seronegative Youth to Optimize HIV Prevention Continuum
The focus of this study (Engaging Seronegative Youth to Optimize HIV Prevention Continuum) - will be to stop HIV-related risk acts and to encourage youth at high risk for HIV to adopt antiretroviral medications as treatment and…
- Conditions
- HIV, Mental Health, Substance Use, STI
- Trial name
- NCT03134833
- Testing
- Automated Messaging & Monitoring, Peer Support, Coaching
- Where
- 2 sites in United States
- Volunteers
- 1,478 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV Infections
Resistance to HIV Infection
The immune systems of some individuals may be capable of resisting HIV infection. These individuals do not appear to be infected with HIV despite multiple sexual encounters with HIV infected partners.
- Trial name
- NCT00069485
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use
This Phase 1 clinical trial will evaluate MIV-150, a third generation non-nucleoside reverse transcriptase inhibitor, co-formulated with a potentially potent agent, zinc acetate for the prevention of HIV infection in women.
- Trial name
- NCT02033109
- Testing
- PC-1005, HEC gel
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Population Council
HIV, Hepatitis C
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
The investigator believes simeprevir concentrations are unchanged when administered in combination with dolutegravir relative to administration alone.
- Trial name
- NCT02404805
- Testing
- dolutegravir, simeprevir
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
HIV Infections, HIV Seronegativity
HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
The purpose of this study is to determine the best way to administer the candidate HIV vaccine, ALVAC HIV-1 (vCP205).
- Trial name
- NCT00013572
- Testing
- ALVAC-HIV MN120TMG (vCP205)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
HIV-1-infection, Hepatic Impairment
Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.
This is an open-label, parallel-group, nonrandomized, multi-centre, phase-IV, single dose trial in 8 HIV-seronegative subjects with severe hepatic impairment and 8 matched controls to assess the pharmacokinetics of a single dose…
- Trial name
- POLO (NCT03813979)
- Testing
- Dolutegravir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
HIV Infections
A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects
To evaluate the safety and immunogenicity of HIV p17/p24:Ty-VLP (virus-like particles) vaccine in uninfected volunteers. Specifically, to determine whether the vaccine formulated with and without alum induces CD8+ cytotoxic T…
- Trial name
- NCT00001053
- Testing
- HIV p17/p24:Ty-VLP, Aluminum hydroxide
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
A Study of GENEVAX-HIV, a Possible Vaccine
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug…
- Trial name
- NCT00002232
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
HIV Infection and Chronic Alanine Aminotransferase Elevation
Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection.
- Trial name
- NCT01208376
- Testing
- Fibroscan
- Where
- Switzerland
- Volunteers
- 195 people
- Sponsor
- Helen Kovari-Kramer
HIV Infections
Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
The purpose of the study is to determine the safety of mucosal immune responses to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
- Trial name
- NCT00955006
- Testing
- VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
HIV Antiretroviral Drugs and Metabolism
Hypothesis 1: Ritonavir-based regimens increase triglycerides and VLDL by both increasing VLDL production and decreasing VLDL clearance.
- Trial name
- NCT00525239
- Testing
- ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infections, HIV Seronegativity
Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to HIV-negative volunteers. This study will also look at how this vaccine affects the immune system of these volunteers.
- Trial name
- NCT00002231
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
HIV Negative, Adaptive Immunity
Immune Responses to Two Experimental HIV Vaccines in Healthy Adults
Background: The primary focus of the Vaccine Research Center (VRC) at the NIH is to develop vaccines for HIV/AIDS. The main purpose of this study is to look in detail at the body s immune response to two experimental HIV vaccines…
- Conditions
- HIV Negative, Adaptive Immunity, Innate Immunity
- Trial name
- NCT01386489
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults
Investigators will examine the safety of and immune responses to two vaccines expressing synthetic HIV proteins: NYVAC-B (a poxvirus), and rAd5 (an adenovirus).
- Trial name
- NCT00961883
- Testing
- NYVAC-B, rAd5
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
HIV Infections, HIV Seronegativity
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV.
- Conditions
- HIV Infections, HIV Seronegativity, Herpes Genitalis
- Trial name
- NCT00076232
- Testing
- Acyclovir
- Where
- 3 sites in United States
- Volunteers
- 3,682 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
Most currently approved anti-HIV drugs work by stopping the replication of HIV after it has entered cells. AMD070 (also known as AMD11070) is designed to block HIV from entering cells and may be effective in treating patients who…
- Trial name
- NCT00063804
- Testing
- Ritonavir, AMD070
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects
To evaluate the safety and immunogenicity of a new microparticulate formulation of an HIV-1 MN PND peptide for oral administration in healthy, HIV-1 seronegative adult volunteers at low risk for infection.
- Trial name
- NCT00000798
- Testing
- HIV-1 Peptide Vaccine, Microparticulate Monovalent
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers
Metabolic changes commonly occur in HIV therapy. The purpose of this study is to assess the impact on insulin sensitivity from the administration of tenofovir disoproxil fumarate 300 mg compared with placebo in non-HIV-1 infected…
- Trial name
- NCT00648817
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
HIV Prevention
Rectal Microbicide Acceptability, Tolerability and Adherence
MTN-035 is a multi-site, randomized-sequence, three-period, open label crossover study that will enroll approximately 210 participants randomized (1:1:1:1:1:1) to one of six sequences of rectal microbicide placebo product…
- Trial name
- NCT03671239
- Where
- 7 sites in United States, Malawi and 3 more
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Microbicide Trials Network